Article in Antimicrobial agents and chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
7 authors.
Xiaofen LiuInstitute of Antibiotics, Huashan Hospital Affiliated to Fudan University, Key Laboratory of Clinical Pharmacology of the National Health Commission, National Clinical Research Center for Aging and Diseases, Shanghai, USA.ORCID 0000-0002-5526-1502
Xingyi QuInstitute of Antibiotics, Huashan Hospital Affiliated to Fudan University, Key Laboratory of Clinical Pharmacology of the National Health Commission, National Clinical Research Center for Aging and Diseases, Shanghai, USA.
Ruohao ZhangInstitute of Antibiotics, Huashan Hospital Affiliated to Fudan University, Key Laboratory of Clinical Pharmacology of the National Health Commission, National Clinical Research Center for Aging and Diseases, Shanghai, USA.
Yuxin ZhangInstitute of Antibiotics, Huashan Hospital Affiliated to Fudan University, Key Laboratory of Clinical Pharmacology of the National Health Commission, National Clinical Research Center for Aging and Diseases, Shanghai, USA.
Xingchen BianClinical Pharmacology Center, Huashan Hospital Affiliated to Fudan University, Shanghai, USA.
Yu-Wei LinInfection Program and Department of Microbiology, Monash Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.
Jing ZhangInstitute of Antibiotics, Huashan Hospital Affiliated to Fudan University, Key Laboratory of Clinical Pharmacology of the National Health Commission, National Clinical Research Center for Aging and Diseases, Shanghai, USA.ORCID 0000-0003-2966-9149
Funding
Huashan Hospital 2023-YN009Ministry of Science and Technology of the People's Republic of China 2017ZX09304005
6 · The paper itself
Abstract
MRX-8 is a new next-generation polymyxin with potent antibacterial activity against carbapenem-resistant
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Synergistic combination of next-generation polymyxin MRX-8 and meropenem against carbapenem-resistant · full record | OpenQuestion